Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
Using an integrated omics approach, researchers identified non-muscle invasive bladder cancer subtypes, along with pathways that are frequently altered in the disease.
The company believes the approach could allow researchers to profile tumor signaling pathways via blood or urine samples, similar to how ctDNA analysis is used.
